Precision BioSciences Prioritizes HBV, DMD Gene Editing Programs Amidst Cash Runway
Event summary
- Precision BioSciences (DTIL) expects ~$137 million in cash, cash equivalents, and restricted cash as of December 31, 2025, providing a runway through 2028.
- The Phase 1/2a ELIMINATE-B trial for chronic Hepatitis B (PBGENE-HBV) has shown dose-dependent antiviral activity and is expanding to include additional cohorts with shorter dosing intervals.
- The Phase 1/2 FUNCTION-DMD trial for Duchenne Muscular Dystrophy (PBGENE-DMD) is expected to dose the first patient in late Q1/early Q2 2026.
- Precision received an $8 million milestone payment from Imugene related to progress with the Azer-Cel CAR-T therapy.
The big picture
Precision BioSciences' focus on HBV and DMD highlights the growing interest in gene editing therapies for previously intractable diseases. While the ARCUS platform holds promise, the company's financial runway and reliance on partner progress create inherent risks. The success of these programs will be a key test of the viability of in vivo gene editing approaches in addressing significant unmet medical needs.
What we're watching
- Clinical Efficacy
- The durability of the antiviral response in the ELIMINATE-B trial will be critical to demonstrating a potential cure for Hepatitis B and justifying further development.
- Regulatory Path
- The FDA’s feedback on the FUNCTION-DMD trial design and initial data will dictate the speed and likelihood of a potential Biologics License Application.
- Partner Performance
- Imugene and iECURE’s progress with Azer-Cel and ECUR-506, respectively, will impact Precision’s future milestone payments and royalty revenue.
Related topics